Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 4, 2006, Pages 724-727

  Özer, Suzan ^a   Arsava, Murat ^a   Ertuǧrul, Aygün ^a   Demir, Başaran ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antipsychotic agents; Obsessive compulsive disorder; Quetiapine; Schizophrenia

Indexed keywords

FLUOXETINE; LORAZEPAM; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ANAMNESIS; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL FEATURE; DELUSION; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; LABORATORY TEST; OBSESSIVE COMPULSIVE DISORDER; PARANOID SCHIZOPHRENIA; SYMPTOMATOLOGY; VISUAL HALLUCINATION;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SCHIZOPHRENIA;

EID: 33646689131     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.11.030     Document Type: Article

References (20)

1. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., and Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9 (1997) 1-17
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth ed. (1994), American Psychiatric Association, Washington, DC
3. Arranz M.J., Munro J., Sham P., Kirov G., Murray R.M., Collier D.A., et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 32 (1998) 93-99
4. Aubry J.-M., Simon A.E., and Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry 61 (2000) 649-655
5. Barr L.C., Goodman W.K., and Price L.H. The serotonin hypothesis of obsessive-compulsive disorder. Int Clin Psychopharmacol 5 (1993) 795-825
6. Bogan A.M., Koran L.M., Chuong H.W., Vapnik T., and Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 66 (2005) 73-79
7. Denys D., van Megen H., and Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 63 (2002) 700-703
8. Enoch M.A., Kaye W.H., Rotondo A., Greenberg B.D., Murphy D.L., and Goldman D. 5-HT2A promoter polymorphism - 1438G/A, anorexia nervosa, and obsessive-compulsive disorder. Lancet 351 (1998) 1785-1786
9. Gefvert O., Lundberg T., Wieselgren I.M., Bergstrom M., Langstrom B., Wiesel F., et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11 (2001) 105-110
10. Kapur S., and Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158 (2001) 360-369
11. Khullar A., Chue P., and Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 26 (2001) 55-59
12. Lane H.Y., Hsu S.K., Liu Y.C., Chang Y.C., Huang C.H., and Chang W.H. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 25 (2005) 6-11
13. Lykouras L., Alevizos B., Michalopoulou P., and Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 333-346
14. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., and Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57 (2000) 794-801
15. Meltzer H.Y., and Kessler H.R. Quetiapine produces preferential occupancy of extrastriatal D2 receptors. Presentation at the 155th annual meeting of the American Psychiatric Association, Philadelphia, PA, May, 18-23 (2002)
16. Potenza M.N., and McDougle C.J. Potential of atypical antipsychotics in the treatment of non-psychotic disorders. CNS Drugs 9 (1998) 213-232
17. Sareen J., Kirshner A., Lander M., Kjernisted K.D., Eleff M.K., and Reiss J.P. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review. J Affect Disord 82 (2004) 167-174
18. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
19. Szekeres G., Keri S., Juhasz A., Rimanoczy A., Szendi I., Czimmer C., et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124 (2004) 1-5
20. Tibbo P., and Warneke L. Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. J Psychiatry Neurosci 24 (1999) 15-24